Key result
Review highlights current and novel diagnostic and therapeutic strategies for AL cardiac amyloidosis.
Why the study?
Cardiac involvement in amyloidosis, particularly light-chain (AL) amyloidosis, carries the worst prognosis and requires updated understanding of diagnosis and treatment approaches.
This review summarizes current and novel approaches to the diagnosis and treatment of AL cardiac amyloidosis.
The amyloidoses are a group of protein-folding disorders in which ≥1 organ is infiltrated by proteinaceous deposits known as amyloid. The deposits are derived from 1 of several amyloidogenic precursor proteins, and the prognosis of the disease is determined both by the organ(s) involved and the type of amyloid. Amyloid involvement of the heart (cardiac amyloidosis) carries the worst prognosis of any involved organ, and light-chain (AL) amyloidosis is the most serious form of the disease. The last decade has seen considerable progress in understanding the amyloidoses. In this review, current and novel approaches to the diagnosis and treatment of cardiac amyloidosis are discussed, with particular reference to AL amyloidosis in the heart.
No takes yet. Share an insight, caveat, or question.
Falk et al. (2016) conducted a review in AL (Light-Chain) Cardiac Amyloidosis. This review discusses current and novel approaches to the diagnosis and treatment of cardiac amyloidosis, with particular reference to AL amyloidosis in the heart.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: